5 completed, 1 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
Follow Adult Disease: new trials by email Literature Review of Adult Disease trials Research Report on Adult Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors TT125-802 - Advanced Solid Tumor, Adult Solid Tumor | Phase 1 | Completed | TOLREMO therapeutics AG | 45 | 2023-11-07 | 2026-07-07 |
| Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer HPVDC injection level dose 1, placebo injection level dose 1, HPVDC injection level dose 2 - Head and Neck Carcinoma, Adult Disease | Phase 1 / Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 24 | 2023-07-31 | 2026-09-18 |
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab - Multiple Myeloma, Relapsed Cancer | Phase 1 | Terminated | Anaveon AG | 4 | 2023-02-10 | 2024-02-12 |
| A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). ANV419 - Melanoma (Skin), Cutaneous Melanoma | Phase 1 / Phase 2 | Completed | Anaveon AG | 29 | 2022-12-16 | 2025-08-26 |
| A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer. ANV419, Ipilimumab - Advanced Solid Tumor, Adult Disease | Phase 1 | Completed | Anaveon AG | 55 | 2021-05-25 | 2024-11-08 |
| Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior Home-based exercise, Education, Exercise plus Education - Multiple Sclerosis, Adult Disease | Phase 1 / Phase 2 | Completed | University of Illinois at Urbana-Champaign | 37 | 2013-04-01 | 2014-11-25 |
Disease (6) · Neoplasms (4) · Recurrence (2) · Hematologic Diseases (1) · Lung Neoplasms (1) · Melanoma (1) · Multiple Myeloma (1) · Multiple Sclerosis (1) · Neoplasm Metastasis (1)
Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Disease Attributes (2) · Immune System Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1)
Dexamethasone (1) · Educational Status (1) · Exercise (1) · Ipilimumab (1) · Lenalidomide (1) · daratumumab (1)
Anaveon AG (3) · Gustave Roussy, Cancer Campus, Grand Paris (1) · TOLREMO therapeutics AG (1) · University of Illinois at Urbana-Champaign (1)
Spain (4) · France (3) · Switzerland (3) · United States (3) · Germany (2) · Denmark (1) · Italy (1) · United Kingdom (1)
Eduard Gasal, MD (3) · Jacob Sosnoff (1)